荣泰健康(603579) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 394,971,319.77, a decrease of 1.41% compared to CNY 400,613,890.42 in the same period last year[4]. - Net profit attributable to shareholders decreased by 29.97% to CNY 43,938,868.26 from CNY 62,741,790.01 year-on-year[4]. - The basic earnings per share (EPS) fell by 32.43% to CNY 0.25, down from CNY 0.37 in the previous year[4]. - Total revenue for Q1 2025 was CNY 394,971,319.77, a decrease of 1.6% from CNY 400,613,890.42 in Q1 2024[21]. - Net profit for Q1 2025 was CNY 43,998,236.11, down 30.0% from CNY 62,847,346.26 in Q1 2024[22]. - Earnings per share (EPS) for Q1 2025 was CNY 0.25, compared to CNY 0.37 in Q1 2024[23]. - The company reported a total comprehensive income of CNY 68,111,591.28 for Q1 2025, compared to CNY 60,953,288.76 in Q1 2024[23]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,354,188,533.65, a decline of 10.36% from CNY 3,742,040,010.16 at the end of the previous year[5]. - Current assets totaled RMB 1,897,601,555.66, down from RMB 2,177,791,254.00[16]. - Total liabilities amounted to CNY 1,278,059,295.89, a decrease from CNY 1,726,421,575.63 year-over-year[18]. - Total equity attributable to shareholders increased to CNY 2,074,584,865.54 from CNY 2,014,115,666.39 in the previous year[18]. Cash Flow - The net cash flow from operating activities improved to CNY -34,477,414.01, compared to CNY -150,370,360.33 in the same period last year, indicating a significant improvement[4]. - Cash inflow from operating activities totaled CNY 465,077,173.97, an increase from CNY 434,769,564.08 in Q1 2024[25]. - The net cash flow from investment activities was $452.73 million, compared to -$88.45 million in the prior period[26]. - Cash inflow from financing activities was $45.66 million, down from $265.55 million in the previous year[26]. - The ending cash and cash equivalents balance was $603.67 million, compared to $1.31 billion at the end of the previous period[26]. Shareholder Information - The top shareholder, Lin Qi, holds 25.58% of the shares, with a total of 45,370,299 shares[10]. - The company has identified several shareholders with significant holdings, including Lin Qi with 45,370,299 shares[11]. - The company held 2,303,200 shares in its repurchase account, representing 1.30% of total shares[12]. Legal Matters - The company was ordered to pay RMB 5.1 million in damages related to a patent infringement lawsuit[13]. - The company is currently involved in a legal dispute regarding patent rights, with an uncertain outcome pending[14]. Operational Costs and Expenses - Total operating costs increased to CNY 359,966,503.86, up 8.6% from CNY 331,559,198.75 in the same period last year[21]. - Research and development expenses for Q1 2025 were CNY 21,310,597.42, up from CNY 20,142,315.83 in Q1 2024[22]. Other Financial Metrics - The weighted average return on equity (ROE) was 2.16%, down from 3.14% in the previous year, reflecting a decrease of 0.98 percentage points[5]. - Non-recurring gains and losses totaled CNY 11,472,634.84, with government subsidies contributing CNY 2,615,365.88[7]. - The company’s deferred income tax liabilities rose to CNY 15,399,670.99 from CNY 9,196,242.74 year-over-year[18].